What is GLOBAL CORD BLOOD CORP's earnings per share (EPS)?

GLOBAL CORD BLOOD CORP (CORBF) reported diluted earnings per share of $0.65 for fiscal year 2022. This represents a 1.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

GLOBAL CORD BLOOD CORP (CORBF) Financials

CORBF

FY2022 annual

Revenue $196.1M +10.8% YoY

Net Income $79.0M +1.9% YoY

EPS (Diluted) $0.65 +1.6% YoY

Free Cash Flow $93.7M +0.6% YoY

Market Cap $127.4M as of Oct 21, 2026

Price / Sales 0.6x on $196.1M revenue, FY2022

Price / Earnings 1.6x on $79.0M net income, FY2022

Price / Book 0.2x on $769.7M equity, Q4 FY2022

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 21, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period FY2022, ended Mar 31, 2022 Reported Aug 16, 2022 Currency USD FYE March

Newest figures come from the 10-K for FY2022, filed Aug 16, 2022. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CORBF SEC filings page.

GLOBAL CORD BLOOD CORP (CORBF) reported $196.1M in revenue for fiscal year 2022, up 10.8% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CORBF FY2022 2026-10-03

The business converts most reported profit into cash, needs little reinvestment, and is financing asset growth increasingly through equity.

From FY2020 to FY2022, operating margin widened from 45.8% to 49.0%, showing operating costs grew more slowly than sales. But net margin moved the other way as the tax burden rose faster than operating income, so the improvement was concentrated above the tax line rather than fully reaching net earnings.

In FY2022, operating cash flow was $96.8M and free cash flow was $93.7M; because the two are close, only a small portion of cash generation was absorbed by capital spending. This relationship also appears across the five reported years, making cash conversion a recurring operating feature rather than a one-year effect.

Between FY2020 and FY2022, debt-to-equity fell from 0.9x to 0.7x as equity accumulated faster than liabilities. The current ratio reached 10.7x in FY2022, indicating that short-term liquidity is not the main financing constraint.

Financial Health Signals

Financial health score not available

GLOBAL CORD BLOOD CORP does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Grey Zone

1.87

GLOBAL CORD BLOOD CORP scores 1.87, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

6/8

GLOBAL CORD BLOOD CORP passes 6 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Cash-Backed

1.22x

For every $1 of reported earnings, GLOBAL CORD BLOOD CORP generates $1.22 in operating cash flow ($96.8M OCF vs $79.0M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

None of these metrics is reported for Q4 2022.

Cash & Balance Sheet

Cash & Debt

$1.1B

YoY+13.3%

QoQ+5.9%

5Y CAGR+37.9%

GLOBAL CORD BLOOD CORP held $1.1B in cash as of Q4 2022; long-term debt is not reported for that period.

Shares Outstanding

122M

YoY0.0%

QoQ0.0%

5Y CAGR+12.0%

GLOBAL CORD BLOOD CORP had 122M shares outstanding in Q4 2022. That is unchanged from the same quarter a year earlier. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q4 2022.

Dividends Per Share

Not reported for Q4 2022.

Margins & Returns

None of these metrics is reported for Q4 2022.

Capital Allocation

None of these metrics is reported for Q4 2022.

CORBF Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CORBF quarterly income statement

Metric	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Revenue	$196.1M+10.8%	$177.0M+2.6%	$172.5M+17.3%	$147.0M-1.5%	$149.3M+35.3%	$110.4M+7.4%	$102.8M+0.4%	$102.5M+11.2%	$92.2M+8.8%	$84.7M+40.2%	$60.4M
Cost of Revenue	$28.9M+5.9%	$27.3M+2.3%	$26.7M-3.6%	$27.7M	N/A	N/A	N/A	N/A	N/A	$17.2M+24.8%	$13.8M
Gross Profit	$167.2M+11.7%	$149.7M+2.7%	$145.8M+22.2%	$119.3M-0.9%	$120.4M+34.3%	$89.7M+11.6%	$80.4M-1.2%	$81.4M+8.4%	$75.1M+11.1%	$67.5M+44.8%	$46.7M
R&D Expenses	$3.5M-3.1%	$3.6M+21.7%	$3.0M+36.2%	$2.2M+7.9%	$2.0M+34.7%	$1.5M+8.3%	$1.4M-13.0%	$1.6M+1.7%	$1.6M+15.4%	$1.4M+12.7%	$1.2M
SG&A Expenses	$29.5M+10.9%	$26.6M-0.9%	$26.9M+6.5%	$25.2M-35.0%	$38.8M+40.7%	$27.6M+4.7%	$26.4M+24.1%	$21.2M+17.6%	$18.1M+3.8%	$17.4M+22.1%	$14.2M
Operating Income	$96.0M+15.5%	$83.2M+5.3%	$79.0M+38.8%	$56.9M+27.5%	$44.6M+16.0%	$38.5M+29.7%	$29.7M-21.7%	$37.9M+1.6%	$37.3M+10.7%	$33.7M+57.4%	$21.4M
EBITDA	$103.6M+14.3%	$90.7M+5.5%	$85.9M+32.9%	$64.7M+22.8%	$52.7M+15.0%	$45.8M+22.3%	$37.5M-18.7%	$46.1M+6.5%	$43.3M+9.6%	$39.5M+51.4%	$26.1M
Interest Expense	N/A	N/A	N/A	N/A	$519K-97.0%	$17.3M+3.6%	$16.7M+2.7%	$16.3M+44.7%	$11.3M-0.1%	$11.3M+2062.1%	$522K
Income Tax	$18.7M+29.4%	$14.4M+1.1%	$14.3M+56.4%	$9.1M-8.6%	$10.0M+82.7%	$5.5M-29.5%	$7.8M+1.6%	$7.6M-18.7%	$9.4M+51.4%	$6.2M+305.6%	$1.5M
Net Income	$79.0M+1.9%	$77.6M+16.7%	$66.5M+53.2%	$43.4M+14.8%	$37.8M+106.2%	$18.3M+29.9%	$14.1M-18.5%	$17.3M-18.4%	$21.2M+17.2%	$18.1M-13.6%	$21.0M
EPS (Basic)	$0.65+1.6%	$0.64+16.4%	$0.55+52.8%	$0.36+9.1%	$0.33+43.5%	$0.23+21.1%	$0.19-13.6%	$0.22-15.4%	$0.26+8.3%	$0.24-14.3%	$0.28
EPS (Diluted)	$0.65+1.6%	$0.64+16.4%	$0.55+52.8%	$0.36+12.5%	$0.32+39.1%	$0.23+21.1%	$0.19-13.6%	$0.22-15.4%	$0.26+8.3%	$0.24-14.3%	$0.28
Diluted Shares (Avg)	N/A	122M0.0%	122M+0.1%	121M+1.8%	119M+63.5%	73M0.0%	73M	N/A	N/A	N/A	N/A

Metric	Q4'2210-K	Q2'2210-Q	Q4'2110-K	Q2'2110-Q	Q4'2010-K	Q2'2010-Q	Q4'1910-K	Q2'1910-Q
Revenue	N/A	$48.7M+15.7%	N/A	$42.1M-4.1%	N/A	$43.9M+21.9%	N/A	$36.0M+2.0%
Cost of Revenue	N/A	$7.2M+8.9%	N/A	$6.6M-2.6%	N/A	$6.8M-1.8%	N/A	$6.9M
Gross Profit	N/A	$41.5M+17.0%	N/A	$35.5M-4.3%	N/A	$37.1M+27.5%	N/A	$29.1M+2.5%
R&D Expenses	N/A	$865K+18.7%	N/A	$729K-18.5%	N/A	$895K+71.1%	N/A	$523K-5.1%
SG&A Expenses	N/A	$6.9M+9.9%	N/A	$6.3M-9.1%	N/A	$6.9M+18.8%	N/A	$5.8M-26.6%
Operating Income	N/A	$24.9M+21.5%	N/A	$20.5M+1.4%	N/A	$20.2M+32.5%	N/A	$15.3M+33.0%
EBITDA	N/A	$26.6M+20.4%	N/A	$22.1M+1.6%	N/A	$21.8M+27.9%	N/A	$17.0M+29.5%
Income Tax	N/A	$4.4M+30.1%	N/A	$3.4M+9.1%	N/A	$3.1M+42.2%	N/A	$2.2M-0.5%
Net Income	N/A	$19.5M+0.8%	N/A	$19.4M+15.0%	N/A	$16.8M+77.6%	N/A	$9.5M-6.7%
EPS (Basic)	N/A	$0.160.0%	N/A	$0.16+14.3%	N/A	$0.14+75.0%	N/A	$0.08-11.1%
EPS (Diluted)	N/A	$0.160.0%	N/A	$0.16+14.3%	N/A	$0.14+75.0%	N/A	$0.08-11.1%
Diluted Shares (Avg)	N/A	N/A	N/A	N/A	N/A	122M-0.1%	N/A	122M+7.2%

Not reported in any period shown, so not listed: Interest Expense.

CORBF Balance Sheet

CORBF quarterly balance sheet

Metric	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Total Assets	$1.3B+11.6%	$1.2B+18.3%	$1.0B+4.5%	$976.1M+4.8%	$931.7M+23.7%	$753.0M+3.6%	$727.0M+9.4%	$664.5M+13.8%	$584.1M+21.5%	$480.8M+66.0%	$289.7M
Current Assets	$1.1B+13.8%	$961.3M+20.1%	$800.2M+4.3%	$767.1M+9.1%	$702.8M+31.8%	$533.4M+7.5%	$496.3M+17.3%	$423.0M+27.8%	$331.1M+28.7%	$257.3M+80.6%	$142.5M
Cash & Equivalents	$1.1B+13.3%	$927.3M+20.0%	$773.0M+3.8%	$744.7M+9.9%	$677.6M+21.1%	$559.6M+28.0%	$437.1M+15.7%	$377.9M+24.4%	$303.7M+26.4%	$240.3M+87.9%	$127.9M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$7.2M+7.1%	$6.8M+9.3%	$6.2M+50.2%	$4.1M-6.9%	$4.4M-1.8%	$4.5M+2.5%	$4.4M+14.4%	$3.8M-24.4%	$5.1M+207.5%	$1.7M+56.0%	$1.1M
Accounts Receivable	$25.4M+27.9%	$19.9M+35.1%	$14.7M+1.9%	$14.4M-16.0%	$17.2M+5.1%	$16.3M-15.4%	$19.3M-0.8%	$19.5M+27.1%	$15.3M+30.3%	$11.8M-6.2%	$12.5M
Long-Term Investments	$14.7M-18.3%	$18.0M+25.8%	$14.3M-10.6%	$16.0M	$0	$0	$0	$0	$0-100.0%	$30.5M+42.7%	$21.3M
Total Liabilities	$575.7M+7.2%	$536.9M+14.1%	$470.5M+0.9%	$466.1M+7.3%	$434.5M-10.5%	$485.3M+5.2%	$461.3M+11.0%	$415.6M+17.9%	$352.5M+25.5%	$280.9M+200.6%	$93.5M
Current Liabilities	$102.0M+6.7%	$95.6M+18.6%	$80.6M-9.2%	$88.8M+18.9%	$74.6M-64.5%	$210.2M+189.5%	$72.6M+7.2%	$67.8M+6.0%	$63.9M+19.4%	$53.5M+71.0%	$31.3M
Non-Current Liabilities	$473.7M+7.3%	$441.3M+13.2%	$389.9M+3.3%	$377.4M+4.9%	$359.9M+30.8%	$275.1M-29.2%	$388.7M+11.7%	$347.8M+20.5%	$288.5M+26.9%	$227.4M+265.9%	$62.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$121.0M	N/A
Total Equity	$769.7M+15.1%	$668.8M+22.0%	$548.3M+7.7%	$509.2M+2.6%	$496.3M+85.9%	$267.0M+0.7%	$265.1M+6.9%	$248.1M+7.5%	$230.8M+15.9%	$199.2M+4.3%	$191.0M
Retained Earnings	$455.5M+25.1%	$364.2M+37.3%	$265.2M+26.5%	$209.7M+17.8%	$178.1M+39.3%	$127.8M+9.4%	$116.9M+9.3%	$106.9M+19.7%	$89.3M+31.0%	$68.2M+38.1%	$49.4M

Metric	Q4'2210-K	Q2'2210-Q	Q4'2110-K	Q2'2110-Q	Q4'2010-K	Q2'2010-Q	Q4'1910-K	Q2'1910-Q
Total Assets	$1.3B+11.6%	$1.3B+14.9%	$1.2B+18.3%	$1.1B+14.7%	$1.0B+4.5%	$972.5M+7.8%	$976.1M+4.8%	$902.4M+7.9%
Current Assets	$1.1B+13.8%	$1.0B+17.3%	$961.3M+20.1%	$880.0M+14.1%	$800.2M+4.3%	$771.2M+10.9%	$767.1M+9.1%	$695.1M+12.7%
Cash & Equivalents	$1.1B+13.3%	$991.8M+17.5%	$927.3M+20.0%	$843.9M+12.4%	$773.0M+3.8%	$751.0M+11.9%	$744.7M+9.9%	$671.4M+13.7%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$7.2M+7.1%	$5.3M-36.5%	$6.8M+9.3%	$8.3M+115.6%	$6.2M+50.2%	$3.8M-19.1%	$4.1M-6.9%	$4.7M-18.7%
Accounts Receivable	$25.4M+27.9%	$22.5M+25.2%	$19.9M+35.1%	$17.9M+32.0%	$14.7M+1.9%	$13.6M-10.9%	$14.4M-16.0%	$15.2M-9.2%
Long-Term Investments	$14.7M-18.3%	$16.9M-4.8%	$18.0M+25.8%	$17.8M+8.2%	$14.3M-10.6%	$16.4M	$16.0M	$0
Total Liabilities	$575.7M+7.2%	$559.5M+11.0%	$536.9M+14.1%	$503.9M+10.0%	$470.5M+0.9%	$457.9M+7.9%	$466.1M+7.3%	$424.6M+9.3%
Current Liabilities	$102.0M+6.7%	$101.0M+15.2%	$95.6M+18.6%	$87.7M+3.3%	$80.6M-9.2%	$84.8M+13.9%	$88.8M+18.9%	$74.5M-1.6%
Non-Current Liabilities	$473.7M+7.3%	$458.5M+10.1%	$441.3M+13.2%	$416.2M+11.6%	$389.9M+3.3%	$373.1M+6.6%	$377.4M+4.9%	$350.1M+12.0%
Total Equity	$769.7M+15.1%	$720.4M+18.1%	$668.8M+22.0%	$610.0M+18.8%	$548.3M+7.7%	$513.3M+7.7%	$509.2M+2.6%	$476.7M+6.6%
Retained Earnings	$455.5M+25.1%	$411.0M+30.3%	$364.2M+37.3%	$315.5M+37.8%	$265.2M+26.5%	$228.9M+25.3%	$209.7M+17.8%	$182.7M+19.6%

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

CORBF Cash Flow Statement

CORBF quarterly cash flow statement

Metric	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Operating Cash Flow	$96.8M+0.5%	$96.3M+9.2%	$88.1M-25.3%	$118.0M-9.6%	$130.5M+40.9%	$92.6M+2.8%	$90.1M-6.1%	$96.0M+11.3%	$86.2M-7.4%	$93.2M+65.8%	$56.2M
Depreciation & Amortization	$7.6M+0.9%	$7.5M+7.3%	$7.0M-10.5%	$7.8M-3.3%	$8.1M+10.0%	$7.3M-5.7%	$7.8M-4.7%	$8.2M+36.9%	$6.0M+3.2%	$5.8M+23.9%	$4.7M
Stock-Based Compensation	N/A	N/A	N/A	N/A	$13.4M+48.6%	$9.0M-0.6%	$9.1M+241.2%	$2.7M	N/A	N/A	N/A
Capital Expenditures	$3.1M-2.1%	$3.2M-6.8%	$3.4M-25.1%	$4.6M-57.2%	$10.7M+198.1%	$3.6M+39.1%	$2.6M-57.7%	$6.1M-74.7%	$24.1M-33.7%	$36.4M+432.1%	$6.8M
Free Cash Flow	$93.7M+0.6%	$93.1M+9.9%	$84.7M-25.3%	$113.5M-5.3%	$119.8M+34.6%	$89.0M+1.7%	$87.5M-2.6%	$89.9M+44.8%	$62.1M+9.4%	$56.7M+15.0%	$49.3M
Investing Cash Flow	-$3.1M-0.9%	-$3.1M+85.1%	-$20.6M-358.2%	-$4.5M+57.5%	-$10.6M+19.5%	-$13.2M	N/A	N/A	N/A	-$79.5M-307.2%	-$19.5M
Financing Cash Flow	-$1.2M-31.5%	-$927K-62.6%	-$570K+82.0%	-$3.2M-883.8%	-$321K+96.3%	-$8.7M	N/A	N/A	N/A	$99.6M+1504.7%	-$7.1M
Dividends Paid	N/A	N/A	N/A	$2.7M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$711K-96.5%	$20.4M+187.9%	$7.1M

Metric	Q4'2210-K	Q2'2210-Q	Q4'2110-K	Q2'2110-Q	Q4'2010-K	Q2'2010-Q	Q4'1910-K	Q2'1910-Q
Depreciation & Amortization	N/A	$1.7M+6.4%	N/A	$1.6M+3.5%	N/A	$1.6M-11.3%	N/A	$1.8M+5.9%

Not reported in any period shown, so not listed: Operating Cash Flow, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.

CORBF Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CORBF quarterly financial ratios

Metric	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Gross Margin	85.3%+0.7pp	84.6%+0.1pp	84.5%+3.4pp	81.2%+0.5pp	80.6%-0.6pp	81.2%+3.0pp	78.2%-1.2pp	79.4%-2.0pp	81.5%+1.7pp	79.7%+2.5pp	77.2%
Operating Margin	49.0%+2.0pp	47.0%+1.2pp	45.8%+7.1pp	38.7%+8.8pp	29.9%-5.0pp	34.8%+6.0pp	28.9%-8.1pp	37.0%-3.5pp	40.5%+0.7pp	39.8%+4.3pp	35.4%
Net Margin	40.3%-3.5pp	43.8%+5.3pp	38.5%+9.0pp	29.5%+4.2pp	25.3%+8.7pp	16.6%+2.9pp	13.7%-3.2pp	16.9%-6.1pp	23.0%+1.7pp	21.4%-13.3pp	34.7%
Return on Equity	10.3%-1.3pp	11.6%-0.5pp	12.1%+3.6pp	8.5%+0.9pp	7.6%+0.8pp	6.9%+1.6pp	5.3%-1.7pp	7.0%-2.2pp	9.2%+0.1pp	9.1%-1.9pp	11.0%
Return on Assets	5.9%-0.6pp	6.4%-0.1pp	6.5%+2.1pp	4.4%+0.4pp	4.1%+1.6pp	2.4%+0.5pp	1.9%-0.7pp	2.6%-1.0pp	3.6%-0.1pp	3.8%-3.5pp	7.2%
Current Ratio	10.73+0.7x	10.05+0.1x	9.93+1.3x	8.64-0.8x	9.42+6.9x	2.54-4.3x	6.83+0.6x	6.24+1.1x	5.18+0.4x	4.81+0.3x	4.55
Debt-to-Equity	0.75-0.1x	0.80-0.1x	0.86-0.1x	0.920.0x	0.88-0.9x	1.82+0.1x	1.74+0.1x	1.68+0.1x	1.53+0.9x	0.61+0.1x	0.49
Asset Turnover	0.150.0x	0.150.0x	0.170.0x	0.150.0x	0.160.0x	0.150.0x	0.140.0x	0.150.0x	0.160.0x	0.180.0x	0.21
FCF Margin	47.8%-4.8pp	52.6%+3.5pp	49.1%-28.1pp	77.2%-3.1pp	80.2%-0.4pp	80.7%-4.5pp	85.1%-2.6pp	87.7%+20.3pp	67.4%+0.4pp	67.0%-14.7pp	81.7%

Metric	Q4'2210-K	Q2'2210-Q	Q4'2110-K	Q2'2110-Q	Q4'2010-K	Q2'2010-Q	Q4'1910-K	Q2'1910-Q
Gross Margin	N/A	85.3%+0.9pp	N/A	84.4%-0.2pp	N/A	84.6%+3.7pp	N/A	80.9%+0.3pp
Operating Margin	N/A	51.1%+2.4pp	N/A	48.7%+2.7pp	N/A	46.1%+3.7pp	N/A	42.4%+9.8pp
Net Margin	N/A	40.1%-5.9pp	N/A	46.0%+7.6pp	N/A	38.4%+12.0pp	N/A	26.4%-2.5pp
Return on Equity	N/A	2.7%-0.5pp	N/A	3.2%-0.1pp	N/A	3.3%+1.3pp	N/A	2.0%-0.3pp
Return on Assets	N/A	1.5%-0.2pp	N/A	1.7%0.0pp	N/A	1.7%+0.7pp	N/A	1.1%-0.2pp
Current Ratio	10.73+0.7x	10.22+0.2x	10.05+0.1x	10.04+0.9x	9.93+1.3x	9.09-0.2x	8.64-0.8x	9.33+1.2x
Debt-to-Equity	0.75-0.1x	0.780.0x	0.80-0.1x	0.83-0.1x	0.86-0.1x	0.890.0x	0.920.0x	0.890.0x
Asset Turnover	N/A	0.040.0x	N/A	0.040.0x	N/A	0.050.0x	N/A	0.040.0x

Not reported in any period shown, so not listed: FCF Margin.

Where GLOBAL CORD BLOOD CORP Ranks

Frequently Asked Questions

What is GLOBAL CORD BLOOD CORP's annual revenue?

GLOBAL CORD BLOOD CORP (CORBF) reported $196.1M in total revenue for fiscal year 2022. This represents a 10.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is GLOBAL CORD BLOOD CORP's revenue growing?

GLOBAL CORD BLOOD CORP (CORBF) revenue grew by 10.8% year-over-year, from $177.0M to $196.1M in fiscal year 2022.

Is GLOBAL CORD BLOOD CORP profitable?

Yes, GLOBAL CORD BLOOD CORP (CORBF) reported a net income of $79.0M in fiscal year 2022, with a net profit margin of 40.3%.

What is GLOBAL CORD BLOOD CORP's EBITDA?

GLOBAL CORD BLOOD CORP (CORBF) had EBITDA of $103.6M in fiscal year 2022, measuring earnings before interest, taxes, depreciation, and amortization.

What is GLOBAL CORD BLOOD CORP's gross margin?

GLOBAL CORD BLOOD CORP (CORBF) had a gross margin of 85.3% in fiscal year 2022, indicating the percentage of revenue retained after direct costs of goods sold.

What is GLOBAL CORD BLOOD CORP's operating margin?

GLOBAL CORD BLOOD CORP (CORBF) had an operating margin of 49.0% in fiscal year 2022, reflecting the profitability of core business operations before interest and taxes.

What is GLOBAL CORD BLOOD CORP's net profit margin?

GLOBAL CORD BLOOD CORP (CORBF) had a net profit margin of 40.3% in fiscal year 2022, representing the share of revenue converted into profit after all expenses.

What is GLOBAL CORD BLOOD CORP's return on equity (ROE)?

GLOBAL CORD BLOOD CORP (CORBF) has a return on equity of 10.3% for fiscal year 2022, measuring how efficiently the company generates profit from shareholder equity.

What is GLOBAL CORD BLOOD CORP's free cash flow?

GLOBAL CORD BLOOD CORP (CORBF) generated $93.7M in free cash flow during fiscal year 2022. This represents a 0.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is GLOBAL CORD BLOOD CORP's operating cash flow?

GLOBAL CORD BLOOD CORP (CORBF) generated $96.8M in operating cash flow during fiscal year 2022, representing cash generated from core business activities.

What are GLOBAL CORD BLOOD CORP's total assets?

GLOBAL CORD BLOOD CORP (CORBF) had $1.3B in total assets as of fiscal year 2022, including both current and long-term assets.

What are GLOBAL CORD BLOOD CORP's capital expenditures?

GLOBAL CORD BLOOD CORP (CORBF) invested $3.1M in capital expenditures during fiscal year 2022, funding long-term assets and infrastructure.

How much does GLOBAL CORD BLOOD CORP spend on research and development?

GLOBAL CORD BLOOD CORP (CORBF) invested $3.5M in research and development during fiscal year 2022.

How many shares does GLOBAL CORD BLOOD CORP have outstanding?

GLOBAL CORD BLOOD CORP (CORBF) had 122M shares outstanding as of fiscal year 2022.

What is GLOBAL CORD BLOOD CORP's current ratio?

GLOBAL CORD BLOOD CORP (CORBF) had a current ratio of 10.73 as of fiscal year 2022, which is generally considered healthy.

What is GLOBAL CORD BLOOD CORP's debt-to-equity ratio?

GLOBAL CORD BLOOD CORP (CORBF) had a debt-to-equity ratio of 0.75 as of fiscal year 2022, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is GLOBAL CORD BLOOD CORP's return on assets (ROA)?

GLOBAL CORD BLOOD CORP (CORBF) had a return on assets of 5.9% for fiscal year 2022, measuring how efficiently the company uses its assets to generate profit.

What is GLOBAL CORD BLOOD CORP's P/E ratio?

GLOBAL CORD BLOOD CORP (CORBF) trades at 1.6x earnings, its market capitalization divided by net income of $79.0M net income, FY2022. The market capitalization is $127.4M as of Oct 21, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is GLOBAL CORD BLOOD CORP's price-to-sales ratio?

GLOBAL CORD BLOOD CORP (CORBF) trades at 0.6x sales, its market capitalization divided by revenue of $196.1M revenue, FY2022. The market capitalization is $127.4M as of Oct 21, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is GLOBAL CORD BLOOD CORP's Altman Z-Score?

GLOBAL CORD BLOOD CORP (CORBF) has an Altman Z-Score of 1.87, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is GLOBAL CORD BLOOD CORP's Piotroski F-Score?

GLOBAL CORD BLOOD CORP (CORBF) has a Piotroski F-Score of 6 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are GLOBAL CORD BLOOD CORP's earnings high quality?

GLOBAL CORD BLOOD CORP (CORBF) has an earnings quality ratio of 1.22x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.